



AOD-9604

A growth hormone fragment that did not beat placebo

AOD-9604 is unusual in this range for a specific reason: it has actually been tested in proper human obesity trials. Being straight about the outcome matters more than the marketing does — it did not separate from placebo on the primary endpoint.

● In Plain English

Growth hormone does several different things, and researchers hoped they could isolate just the fat-burning part by using only the tail end of the molecule. The theory was elegant: get the fat loss, skip the effects on blood sugar and tissue growth. It was tested properly in people. The tolerability held up; the fat loss did not.

What people use it for. Fat loss, on the theory that it isolates the fat-burning part of growth hormone without the rest.

What to know before you buy. We would rather tell you this than have you find out later: AOD-9604 was tested properly in placebo-controlled human obesity trials, and it did not beat placebo on weight loss. That is unusual in this category, where most compounds have never been tested at all — and it cuts both ways, because it also means the safety data is better than most. It was well tolerated and did not disturb blood sugar or IGF-1. If you want it for tolerability or for the newer joint and cartilage research, that is a defensible reason. If you want it for fat loss, the trial record does not support that.

● What It's Used For

GOAL	WHAT THAT RESTS ON
Favourable tolerability	Well tolerated in human trials, with no significant effect on IGF-1 or blood glucose
Joint and cartilage research	A newer and still early line of investigation
Honest caveat	In placebo-controlled human obesity trials it did not produce significant weight loss versus placebo. We would rather tell you now

The left column lists goals people commonly pursue with this compound; the right column states what that rests on. These are described uses and research findings, not proven outcomes or treatment claims. Individual results vary and no outcome is promised.

● Pricing & Sizes

PRICING

5mg vial

\$45

Bulk pricing: 2-3 vials -5% | 4-6 vials -10% | 7-9 vials -15% | 10+ vials -20%

Ships sealed and lyophilized — stable for years at room temperature, reconstitute before use, or ask and it will be reconstituted free at the volume shown below. **Free shipping on every order, no minimum.** Third-party COA available for every batch — HPLC purity and mass spec verification.

Reconstitution — bacteriostatic water: 5mg vial at 2mL = 2.5mg/mL, so 10 units on a 100-unit syringe draws 0.25mg. Concentrations are arithmetic from vial content and diluent volume, not a dosing recommendation.

● At a Glance

CLASS	Synthetic peptide corresponding to the C-terminal fragment (residues 176-191) of human growth hormone
ORIGINAL RATIONALE	Proposed to carry hGH's fat-metabolising activity without its growth-promoting or glucose effects
CLINICAL TESTING	Developed through phase II for obesity by Metabolic Pharmaceuticals
OUTCOME	Did not demonstrate significant weight loss versus placebo on the primary endpoint; the obesity development programme did not proceed to approval
SAFETY SIGNAL	Generally well tolerated in the trials, with no significant effect on IGF-1 or glucose
REGULATORY (US)	Not FDA-approved. Not on the July 2026 PCAC agenda
FORMAT	5mg vial

176-191

HGH FRAGMENT

Phase II

REACHED AND STOPPED

No

SEPARATION FROM PLACEBO

Well
tolerated

SAFETY PROFILE

EVIDENCE STATUS — READ THIS FIRST

AOD-9604 is one of the few compounds in this category to have completed proper placebo-controlled human obesity trials. **It did not produce statistically significant weight loss versus placebo** on the primary endpoint, and the obesity programme did not advance to approval. Marketing that presents AOD-9604 as a proven fat-loss compound is not consistent with its own trial record. It was not on the July 2026 PCAC agenda.

● What the Trials Showed

The development programme took AOD-9604 through phase II in obesity. The trials achieved something most compounds here never attempt: a real placebo-controlled test of the central claim. The headline result was that the compound did not separate meaningfully from placebo on weight reduction.

The safety findings were genuinely favourable. AOD-9604 did not produce the IGF-1 elevation or glucose effects associated with full-length growth hormone, which is consistent with the design rationale — the fragment does appear to avoid those effects. It simply also appears to avoid producing the intended one at a clinically meaningful level.

Why it remains on the market

Interest persisted partly on the strength of preclinical work and partly through subsequent attention to other possible applications, including cartilage and joint research. Those lines are early and are not the basis on which the compound is usually sold. Its favourable tolerability profile also keeps it in circulation.

THE BOTTOM LINE

A well-designed idea that was properly tested and did not deliver on its primary endpoint. Reliable tolerability, no demonstrated fat-loss efficacy versus placebo. Of everything in this range, AOD-9604 is the compound where the honest evidence summary differs most sharply from the typical sales pitch.

● Also in the Range

Compare with **Tirzepatide** and **Retatrutide** for fat loss, both of which have demonstrated weight reduction in controlled trials where AOD-9604 did not.

Research use only. Products referenced in this document are supplied for laboratory and research purposes only and are **not for human or veterinary consumption**, not for diagnostic use, and not for use in food or cosmetics. They are not sold as drugs, dietary supplements or medical devices. **Not medical advice.** This document summarises publicly available research and is provided for informational and educational purposes only. It is not medical advice, not a diagnosis, not a treatment recommendation, and not an offer or promise to treat, cure, mitigate or prevent any disease or condition. Nothing here should be relied upon in place of advice from a qualified, licensed healthcare professional, and you should consult one before making any health decision. **On the statements made here.** Descriptions of research findings summarise what published studies have reported. They are not claims of safety or efficacy, and they should not be read as representing that any outcome will occur. Where research is preclinical (cell or animal), findings may not translate to humans. Individual results vary, and no particular result is promised or implied. Unless expressly stated otherwise, compounds described here are **not approved by the FDA** for any indication. **Regulatory information.** Regulatory positions described are current as of the date of this document and are subject to change without notice; verify current status independently before relying on it. **Buyer responsibility.** Purchasers are responsible for determining the lawfulness of purchase, possession and use in their jurisdiction. **No warranty.** This information is provided "as is" without warranty of any kind, express or implied. To the fullest extent permitted by law, no liability is accepted for any loss or damage arising from reliance on it. **Pricing.** Prices shown are current as of the date of this document, are subject to change without notice, and do not constitute a binding offer. **Sources:** Metabolic Pharmaceuticals AOD-9604 phase II obesity programme; published AOD-9604 clinical literature; FDA PCAC meeting materials, 23-24 July 2026 (not on agenda).

